Home
Astellas Pharma China, Inc.

Astellas Pharma China, Inc. Market Share Analysis for June 2026

Astellas is a global life sciences company turning science into value for patients through transformative therapies. Discover how we're pioneering new healthcare solutions.

Industry: N/A

Domainastellas.com.cn

Year Founded--

Employees1001 - 5000

Annual Revenue--

Astellas Pharma China, Inc.

Astellas Pharma China, Inc. (including company regionals)

astellas.com.cn

See more website traffic and engagement information

Total visits to Astellas Pharma China, Inc.'s top domains

Understand Astellas Pharma China, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Astellas Pharma China, Inc.'s top domains

Analyze Astellas Pharma China, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Astellas Pharma China, Inc.'s top domains

See how Astellas Pharma China, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Astellas Pharma China, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Astellas Pharma China, Inc.

These are the website technologies, by industry, used by Astellas Pharma China, Inc. top domains

Conversion & Analytics (9)

Google Analytics

Advertising (6)

DoubleClick

Content Management System (3)

Drupal

Marketing (3)

Google Marketing Platform

More Technologies

4

See all

News & Signals from Astellas Pharma China, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAstellas invests into assets: gene therapy manufacturing plant in the amount of $100M in Sanford, North Carolina, United States, Northern America, Americas.Astellas has completed construction of a $100 million gene therapy manufacturing plant in Sanford, North Carolina.

NewsAstellas launches EVRENZO in Germany.Following the European Commission approval of EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD), Astellas has launched EVRENZO™ in Germany, the United Kingdom, Netherlands, Austria, and the Nordic countries.

NewsAstellas partners with Dyno Therapeutics Inc..Astellas partnered with Dyno Therapeutics on viral vectors for gene therapy.